Disease · MONDO_0004739
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NaPBA vs HPN-100: Rate of Adverse Events in Each Treatment Group | 23 of 45 | 27 of 44 | 89 | NCT00992459 | Trial comparisons |
| NaPBA vs HPN-100: serious adverse events | 1 of 45 | 1 of 44 | 89 | NCT00992459 | Trial comparisons |
| HPN-100- Pediatric vs HPN-100 - Adult: Number of Participants With at Least One Adverse Event | 34 of 45 | 40 of 43 | 88 | NCT01257737 | Trial comparisons |
| HPN-100- Pediatric vs HPN-100 - Adult: deaths from any cause | 0 of 45 | 0 of 43 | 88 | NCT01257737 | Trial comparisons |
| HPN-100- Pediatric vs HPN-100 - Adult: serious adverse events | 12 of 45 | 19 of 43 | 88 | NCT01257737 | Trial comparisons |
| NaPBA vs HPN-100: Adverse Events | 0 of 15 | 6 of 15 | 30 | NCT01347073 | Trial comparisons |
| RAVICTI: Age 2 Months to < 2 Years vs RAVICTI: Age 0 to <2 Months: deaths from any cause | 1 of 10 | 0 of 16 | 26 | NCT02246218 | Trial comparisons |
| RAVICTI: Age 2 Months to < 2 Years vs RAVICTI: Age 0 to <2 Months: serious adverse events | 6 of 10 | 11 of 16 | 26 | NCT02246218 | Trial comparisons |
| Buphenyl vs HPN-100: Number of Subjects Experienced Adverse Events | 7 of 14 | 5 of 10 | 24 | NCT00551200 | Trial comparisons |
| Buphenyl vs HPN-100: Number of Subjects Experienced Serious Adverse Events | 1 of 14 | 0 of 10 | 24 | NCT00551200 | Trial comparisons |
| Buphenyl vs HPN-100: serious adverse events | 1 of 14 | 0 of 10 | 24 | NCT00551200 | Trial comparisons |
| HPN-100 vs NaPBA: Rate of Adverse Events During the Switchover Part of the Study Rate of Adverse Events (Number of Participants Showing Adverse Events) | 4 of 11 | 2 of 11 | 22 | NCT00947544 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004739/comparisons